These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25613665)

  • 21. Efficacy and safety of triple-antiplatelet therapy after percutaneous coronary intervention: a meta-analysis.
    Zhang Y; Tang HQ; Li J; Fu ZX
    Chin Med J (Engl); 2013; 126(9):1750-4. PubMed ID: 23652062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention.
    D'Ascenzo F; Taha S; Moretti C; Omedè P; Grossomarra W; Persson J; Lamberts M; Dewilde W; Rubboli A; Fernández S; Cerrato E; Meynet I; Ballocca F; Barbero U; Quadri G; Giordana F; Conrotto F; Capodanno D; DiNicolantonio J; Bangalore S; Reed M; Meier P; Zoccai G; Gaita F
    Am J Cardiol; 2015 May; 115(9):1185-93. PubMed ID: 25799015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
    EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention.
    Lotrionte M; Biondi-Zoccai GG; Agostoni P; Abbate A; Angiolillo DJ; Valgimigli M; Moretti C; Meliga E; Cuisset T; Alessi MC; Montalescot G; Collet JP; Di Sciascio G; Waksman R; Testa L; Sangiorgi G; Laudito A; Trevi GP; Sheiban I
    Am J Cardiol; 2007 Oct; 100(8):1199-206. PubMed ID: 17920357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
    Chen Y; Zhang Y; Tang Y; Huang X; Xie Y
    Curr Med Res Opin; 2014 Jan; 30(1):37-49. PubMed ID: 24083626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
    Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
    Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] trial).
    Patti G; Pasceri V; Mangiacapra F; Colonna G; Vizzi V; Ricottini E; Montinaro A; D'Ambrosio A; Wijns W; Barbato E; Di Sciascio G;
    Am J Cardiol; 2013 Jul; 112(2):162-8. PubMed ID: 23601577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
    Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin.
    Siller-Matula JM; Delle-Karth G; Christ G; Neunteufl T; Maurer G; Huber K; Tolios A; Drucker C; Jilma B
    Int J Cardiol; 2013 Jul; 167(2):430-5. PubMed ID: 22305813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.
    Mrdovic I; Savic L; Krljanac G; Asanin M; Cvetinovic N; Brdar N; Stojanovic M; Djuricic N; Stankovic S; Marinkovic J; Perunicic J
    J Interv Cardiol; 2013 Jun; 26(3):221-7. PubMed ID: 23373620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Chen Y; Zhang Y; Tang Y; Huang X; Xie Y
    PLoS One; 2013; 8(10):e78549. PubMed ID: 24194947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.
    Gibson CM; Murphy SA; Pride YB; Kirtane AJ; Aroesty JM; Stein EB; Ciaglo LN; Southard MC; Sabatine MS; Cannon CP; Braunwald E;
    Am Heart J; 2008 Jan; 155(1):133-9. PubMed ID: 18082504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.
    Tavassoli N; Voisin S; Carrie D; Lapeyre-Mestre M; Galinier M; Montastruc JL; Pathak A
    Am J Cardiovasc Drugs; 2010; 10(1):29-35. PubMed ID: 20104932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery.
    Ferreiro JL; Homs S; Berdejo J; Roura G; Gómez-Lara J; Romaguera R; Teruel L; Sánchez-Elvira G; Marcano AL; Gómez-Hospital JA; Angiolillo DJ; Cequier Á
    Thromb Haemost; 2013 Jul; 110(1):110-7. PubMed ID: 23615769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty.
    Mangiacapra F; Muller O; Ntalianis A; Trana C; Heyndrickx GR; Bartunek J; Vanderheyden M; Wijns W; De Bruyne B; Barbato E
    Am J Cardiol; 2010 Nov; 106(9):1208-11. PubMed ID: 21029814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
    Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
    Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
    Liang J; Wang Z; Shi D; Liu Y; Zhao Y; Han H; Li Y; Liu W; Zhang L; Yang L; Zhou Y
    Angiology; 2015 Apr; 66(4):319-25. PubMed ID: 24913197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Clopidogrel loading dose in patients with chronic kidney disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Kim JY; Jeong MH; Moon JH; Ahn YK; Chae SC; Hur SH; Hong TJ; Kim YJ; Seong IW; Chae IH; Cho MC; Jang YS; Yoon JH; Seung KB; Park SJ;
    Am J Cardiol; 2012 Dec; 110(11):1598-606. PubMed ID: 22935526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Loh JP; Pendyala LK; Kitabata H; Torguson R; Chen F; Kent KM; Satler LF; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2013 Mar; 111(6):841-5. PubMed ID: 23273719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.